Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Prostate Cancer

Free Subscription Articles published in J Clin Oncol Retrieve available abstracts of 58 articles: HTML format

Single Articles

July 2022
1. TISSEVERASINGHE S, Tolba M, Saad F, Gravis G, et al
   Should Prostate Cancer Patients With History of Cardiovascular Events Be Preferentially Treated With Luteinizing Hormone-Releasing Hormone Antagonists?
   J Clin Oncol. 2022 Jul 21:JCO2200883. doi: 10.1200/JCO.22.00883.
   PubMed    
   
   
   June 2022
2. JACKSON WC, Tang M, Schipper MJ, Sandler HM, et al
   Biochemical Failure Is Not a Surrogate End Point for Overall Survival in Recurrent Prostate Cancer: Analysis of NRG Oncology/RTOG 9601.
   J Clin Oncol. 2022 Jun 23:JCO2102741. doi: 10.1200/JCO.21.02741.
   PubMed     Abstract available
   
   
   
3. KARTOLO A, Tannock IF, Vera Badillo FE
   Management of Metastatic Hormone-Sensitive Prostate Cancer: Is Docetaxel Needed?
   J Clin Oncol. 2022 Jun 20:JCO2200705. doi: 10.1200/JCO.22.00705.
   PubMed    
   
   
   
4. MADAN RA, Mena E, Lindenberg L, Choyke PL, et al
   With New Technology Comes Great Responsibility: Prostate-Specific Membrane Antigen Imaging in Recurrent Prostate Cancer.
   J Clin Oncol. 2022 Jun 3:JCO2200493. doi: 10.1200/JCO.22.00493.
   PubMed    
   
   
   
5. BROOKS GA, Landrum MB, Kapadia NS, Liu PH, et al
   Impact of the Oncology Care Model on Use of Supportive Care Medications During Cancer Treatment.
   J Clin Oncol. 2022;40:1763-1771.
   PubMed     Abstract available
   
   
   May 2022
6. CAO Y, Deville C Jr
   Adjuvant Radiation for Pathologically Node-Positive Prostate Cancer: Evidence When Early Salvage May Not Be Early Enough.
   J Clin Oncol. 2022 May 23:JCO2200645. doi: 10.1200/JCO.22.00645.
   PubMed    
   
   
   April 2022
7. AGARWAL N, Tangen CM, Hussain MHA, Gupta S, et al
   Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216).
   J Clin Oncol. 2022 Apr 21:JCO2102517. doi: 10.1200/JCO.21.02517.
   PubMed     Abstract available
   
   
   
8. HUSSAIN M, Carducci MA, Clarke N, Fenton SE, et al
   Evolving Role of Prostate-Specific Membrane Antigen-Positron Emission Tomography in Metastatic Hormone-Sensitive Prostate Cancer: More Questions than Answers?
   J Clin Oncol. 2022 Apr 19:JCO2200208. doi: 10.1200/JCO.22.00208.
   PubMed    
   
   
   
9. EGGENER SE, Berlin A, Vickers AJ, Paner GP, et al
   Low-Grade Prostate Cancer: Time to Stop Calling It Cancer.
   J Clin Oncol. 2022 Apr 18:JCO2200123. doi: 10.1200/JCO.22.00123.
   PubMed    
   
   
   
10. ARMSTRONG AJ, Azad AA, Iguchi T, Szmulewitz RZ, et al
    Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer.
    J Clin Oncol. 2022 Apr 14:JCO2200193. doi: 10.1200/JCO.22.00193.
    PubMed     Abstract available
    
    
    March 2022
11. TILKI D, Chen MH, Wu J, Huland H, et al
    Adjuvant Versus Early Salvage Radiation Therapy After Radical Prostatectomy for pN1 Prostate Cancer and the Risk of Death.
    J Clin Oncol. 2022 Mar 15:JCO2102800. doi: 10.1200/JCO.21.02800.
    PubMed     Abstract available
    
    
    February 2022
12. PATEL NA, Reiter RE
    Impact of a Novel Molecular Imaging Modality, Prostate-Specific Membrane Antigen Positron Emission Tomography, on the Management of Prostate Cancer.
    J Clin Oncol. 2022 Feb 24:JCO2102940. doi: 10.1200/JCO.21.02940.
    PubMed    
    
    
    
13. VAN WAMBEKE S, Vera-Badillo FE, Gyawali B
    Controlling the Control Arm in Metastatic Castration-Resistant Prostate Cancer Trials: Best Standard of Care or the Minimum Standard of Care?
    J Clin Oncol. 2022 Feb 21:JCO2102304. doi: 10.1200/JCO.21.02304.
    PubMed    
    
    
    January 2022
14. SCHODER H, Hope TA, Knopp M, Kelly WK, et al
    Considerations on Integrating Prostate-Specific Membrane Antigen Positron Emission Tomography Imaging Into Clinical Prostate Cancer Trials by National Clinical Trials Network Cooperative Groups.
    J Clin Oncol. 2022 Jan 11:JCO2102440. doi: 10.1200/JCO.21.02440.
    PubMed     Abstract available
    
    
    
15. MORGANS AK, Beltran H
    Isn't Androgen Deprivation Enough? Optimal Treatment for Newly Diagnosed Metastatic Prostate Cancer.
    J Clin Oncol. 2022 Jan 6:JCO2102530. doi: 10.1200/JCO.21.02530.
    PubMed     Abstract available
    
    
    
16. DZIMITROWICZ HE, Armstrong AJ
    Elevating the Patient Voice in Metastatic Hormone-Sensitive Prostate Cancer Clinical Trials.
    J Clin Oncol. 2022 Jan 6:JCO2102504. doi: 10.1200/JCO.21.02504.
    PubMed    
    
    
    December 2021
17. STOCKLER MR, Martin AJ, Davis ID, Dhillon HM, et al
    Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP.
    J Clin Oncol. 2021 Dec 20:JCO2100941. doi: 10.1200/JCO.21.00941.
    PubMed     Abstract available
    
    
    November 2021
18. RUSH HL, Murphy L, Morgans AK, Clarke NW, et al
    Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial.
    J Clin Oncol. 2021 Nov 10:JCO2100728. doi: 10.1200/JCO.21.00728.
    PubMed     Abstract available
    
    
    
19. SADA YH
    A Dozen Eggs.
    J Clin Oncol. 2021;39:3645-3646.
    PubMed    
    
    
    September 2021
20. KERKMEIJER LGW, Pos FJ, Haustermans K, van der Heide UA, et al
    Reply to I. R. Vogelius et al.
    J Clin Oncol. 2021;39:3086-3087.
    PubMed    
    
    
    July 2021
21. BOLLA M, Neven A, Maingon P, Carrie C, et al
    Short Androgen Suppression and Radiation Dose Escalation in Prostate Cancer: 12-Year Results of EORTC Trial 22991 in Patients With Localized Intermediate-Risk Disease.
    J Clin Oncol. 2021 Jul 26:JCO2100855. doi: 10.1200/JCO.21.00855.
    PubMed     Abstract available
    
    
    
22. SPERGER JM, Emamekhoo H, McKay RR, Stahlfeld CN, et al
    Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer.
    J Clin Oncol. 2021 Jul 1:JCO2100169. doi: 10.1200/JCO.21.00169.
    PubMed     Abstract available
    
    
    
23. D'AMICO AV, Xie W, McMahon E, Loffredo M, et al
    Radiation and Androgen Deprivation Therapy With or Without Docetaxel in the Management of Nonmetastatic Unfavorable-Risk Prostate Cancer: A Prospective Randomized Trial.
    J Clin Oncol. 2021 Jul 1:JCO2100596. doi: 10.1200/JCO.21.00596.
    PubMed     Abstract available
    
    
    June 2021
24. VOGELIUS IR, Bentzen SM
    Radiation Dose Escalation for Early Prostate Cancer: Reigniting the FLAME?
    J Clin Oncol. 2021 Jun 4:JCO2100586. doi: 10.1200/JCO.21.00586.
    PubMed    
    
    
    
25. YANG DD, Nguyen PL, D'Amico AV
    Elective Pelvic Lymph Node Radiation in Prostate Cancer Revisited.
    J Clin Oncol. 2021 Jun 4:JCO2100621. doi: 10.1200/JCO.21.00621.
    PubMed    
    
    
    
26. BRENNEMAN RJ, Baumann BC, Gay HA, Michalski JM, et al
    Regarding the Use of PSMA PET-CT Versus Conventional Imaging for Assessing the Value of Prophylactic Whole-Pelvis Radiation for High-Risk Prostate Cancer.
    J Clin Oncol. 2021 Jun 4:JCO2100634. doi: 10.1200/JCO.21.00634.
    PubMed    
    
    
    
27. DESS RT, Jackson WC, Spratt DE
    End Point Definitions and Surrogacy in Prostate Cancer: Will Metastasis-Free Survival Become Event-Free Survival With Advances in Molecular Imaging?
    J Clin Oncol. 2021 Jun 4:JCO2100376. doi: 10.1200/JCO.21.00376.
    PubMed    
    
    
    
28. TILKI D, Chen MH, Wu J, Huland H, et al
    Adjuvant Versus Early Salvage Radiation Therapy for Men at High Risk for Recurrence Following Radical Prostatectomy for Prostate Cancer and the Risk of Death.
    J Clin Oncol. 2021 Jun 4:JCO2003714. doi: 10.1200/JCO.20.03714.
    PubMed     Abstract available
    
    
    May 2021
29. TEWARI AK, Gillessen S, Sweeney CJ
    Metastatic Prostate Cancer: In Search of More Granularity.
    J Clin Oncol. 2021 May 14:JCO2100643. doi: 10.1200/JCO.21.00643.
    PubMed    
    
    
    April 2021
30. HOCHT S, Mason M, Wiegel T
    Timing of ADT in Radiotherapy of Prostate Cancer.
    J Clin Oncol. 2021 Apr 29:JCO2100032. doi: 10.1200/JCO.21.00032.
    PubMed    
    
    
    
31. CHI KN, Chowdhury S, Bjartell A, Chung BH, et al
    Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study.
    J Clin Oncol. 2021 Apr 29:JCO2003488. doi: 10.1200/JCO.20.03488.
    PubMed     Abstract available
    
    
    
32. MURPHY AB, Abern MR, Liu L, Wang H, et al
    Impact of a Genomic Test on Treatment Decision in a Predominantly African American Population With Favorable-Risk Prostate Cancer: A Randomized Trial.
    J Clin Oncol. 2021 Apr 9:JCO2002997. doi: 10.1200/JCO.20.02997.
    PubMed     Abstract available
    
    
    March 2021
33. JAN I, Parikh RR
    Feeding the Controversy: When Pelvic Irradiation Improves Outcomes in High-Risk and Very High-Risk Prostate Cancer.
    J Clin Oncol. 2021 Mar 8:JCO2003636. doi: 10.1200/JCO.20.03636.
    PubMed     Abstract available
    
    
    February 2021
34. DENMEADE SR, Wang H, Agarwal N, Smith DC, et al
    TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer.
    J Clin Oncol. 2021 Feb 22:JCO2002759. doi: 10.1200/JCO.20.02759.
    PubMed     Abstract available
    
    
    January 2021
35. MURTHY V, Maitre P, Kannan S, Panigrahi G, et al
    Prostate-Only Versus Whole-Pelvic Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer (POP-RT): Outcomes From Phase III Randomized Controlled Trial.
    J Clin Oncol. 2021 Jan 26:JCO2003282. doi: 10.1200/JCO.20.03282.
    PubMed     Abstract available
    
    
    
36. VIRGO KS, Rumble RB, de Wit R, Mendelson DS, et al
    Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update.
    J Clin Oncol. 2021 Jan 26:JCO2003256. doi: 10.1200/JCO.20.03256.
    PubMed     Abstract available
    
    
    
37. KERKMEIJER LGW, Groen VH, Pos FJ, Haustermans K, et al
    Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer: Results From the FLAME Randomized Phase III Trial.
    J Clin Oncol. 2021 Jan 20:JCO2002873. doi: 10.1200/JCO.20.02873.
    PubMed     Abstract available
    
    
    
38. SPRATT DE, Malone S, Roy S, Grimes S, et al
    Prostate Radiotherapy With Adjuvant Androgen Deprivation Therapy (ADT) Improves Metastasis-Free Survival Compared to Neoadjuvant ADT: An Individual Patient Meta-Analysis.
    J Clin Oncol. 2021;39:136-144.
    PubMed     Abstract available
    
    
    December 2020
39. CRABB SJ, Griffiths G, Marwood E, Dunkley D, et al
    Pan-AKT Inhibitor Capivasertib With Docetaxel and Prednisolone in Metastatic Castration-Resistant Prostate Cancer: A Randomized, Placebo-Controlled Phase II Trial (ProCAID).
    J Clin Oncol. 2020 Dec 16:JCO2001576. doi: 10.1200/JCO.20.01576.
    PubMed     Abstract available
    
    
    November 2020
40. JACKSON WC, Hartman HE, Dess RT, Spratt DE, et al
    Reply to L. C. Mendez et al and M. A. Kollmeier et al.
    J Clin Oncol. 2020;38:3823-3824.
    PubMed    
    
    
    
41. KOLLMEIER MA, McBride S, Gorovets D, Zelefsky MJ, et al
    Role of Androgen-Deprivation Therapy Remains Uncertain for Intermediate-Risk Patients When Using Dose-Escalated Radiotherapy.
    J Clin Oncol. 2020;38:3821-3822.
    PubMed    
    
    
    October 2020
42. HUSSAIN M, Lin D, Saad F, Vapiwala N, et al
    Newly Diagnosed High-Risk Prostate Cancer in an Era of Rapidly Evolving New Imaging: How Do We Treat?
    J Clin Oncol. 2020 Oct 13:JCO2002268. doi: 10.1200/JCO.20.02268.
    PubMed    
    
    
    
43. DALLA VOLTA A, Mazziotti G, Maffezzoni F, Grisanti S, et al
    Bone Mineral Density and FRAX Score May Not Predict Fracture Risk in Patients With Cancer Undergoing Hormone Deprivation Therapies.
    J Clin Oncol. 2020;38:3363-3366.
    PubMed    
    
    
    September 2020
44. CASTRO MENDEZ L, Martell K, Crook JM
    Brachytherapy and Androgen-Deprivation Therapy in Patients With Intermediate- and High-Risk Prostate Cancer: Not Necessarily an Either/Or Decision.
    J Clin Oncol. 2020 Sep 30:JCO2001566. doi: 10.1200/JCO.20.01566.
    PubMed    
    
    
    
45. KYRIAKOPOULOS CE, Heath EI, Ferrari A, Sperger JM, et al
    Exploring Spatial-Temporal Changes in (18)F-Sodium Fluoride PET/CT and Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide.
    J Clin Oncol. 2020 Sep 8:JCO2000348. doi: 10.1200/JCO.20.00348.
    PubMed     Abstract available
    
    
    
46. SCHWEIZER MT, Cheng HH, Nelson PS, Montgomery RB, et al
    Two Steps Forward and One Step Back for Precision in Prostate Cancer Treatment.
    J Clin Oncol. 2020 Sep 8:JCO2001755. doi: 10.1200/JCO.20.01755.
    PubMed    
    
    
    
47. MARKOWSKI MC, Antonarakis ES
    BRCA1 Versus BRCA2 and PARP Inhibitor Sensitivity in Prostate Cancer: More Different Than Alike?
    J Clin Oncol. 2020 Sep 1:JCO2002246. doi: 10.1200/JCO.20.02246.
    PubMed    
    
    
    August 2020
48. ABIDA W, Patnaik A, Campbell D, Shapiro J, et al
    Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration.
    J Clin Oncol. 2020 Aug 14:JCO2001035. doi: 10.1200/JCO.20.01035.
    PubMed     Abstract available
    
    
    July 2020
49. EASTHAM JA, Heller G, Halabi S, Monk JP 3rd, et al
    Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer.
    J Clin Oncol. 2020 Jul 24:JCO2000315. doi: 10.1200/JCO.20.00315.
    PubMed     Abstract available
    
    
    June 2020
50. XIE W, Regan MM, Buyse M, Halabi S, et al
    Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation.
    J Clin Oncol. 2020 Jun 18:JCO1903114. doi: 10.1200/JCO.19.03114.
    PubMed     Abstract available
    
    
    
51. GIRI VN, Knudsen KE, Kelly WK, Cheng HH, et al
    Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019.
    J Clin Oncol. 2020 Jun 9:JCO2000046. doi: 10.1200/JCO.20.00046.
    PubMed     Abstract available
    
    
    May 2020
52. ROY S, Malone S
    Reply to P. Ghadjar et al.
    J Clin Oncol. 2020;38:1747-1748.
    PubMed    
    
    
    
53. JACKSON WC, Hartman HE, Dess RT, Birer SR, et al
    Addition of Androgen-Deprivation Therapy or Brachytherapy Boost to External Beam Radiotherapy for Localized Prostate Cancer: A Network Meta-Analysis of Randomized Trials.
    J Clin Oncol. 2020 May 12:JCO1903217. doi: 10.1200/JCO.19.03217.
    PubMed     Abstract available
    
    
    
54. LIN DW, Zheng Y, McKenney JK, Brown MD, et al
    17-Gene Genomic Prostate Score Test Results in the Canary Prostate Active Surveillance Study (PASS) Cohort.
    J Clin Oncol. 2020;38:1549-1557.
    PubMed     Abstract available
    
    
    
55. MARSHALL CH, Joshu CE
    Mounting Weight of Evidence on the Importance of Body Weight for Men With Prostate Cancer.
    J Clin Oncol. 2020 May 5:JCO2000791. doi: 10.1200/JCO.20.00791.
    PubMed    
    
    
    April 2020
56. TROESCHEL AN, Hartman TJ, Jacobs EJ, Stevens VL, et al
    Postdiagnosis Body Mass Index, Weight Change, and Mortality From Prostate Cancer, Cardiovascular Disease, and All Causes Among Survivors of Nonmetastatic Prostate Cancer.
    J Clin Oncol. 2020 Apr 6:JCO1902185. doi: 10.1200/JCO.19.02185.
    PubMed     Abstract available
    
    
    February 2020
57. AGOCHUKWU NQ, Wittmann D, Boileau NR, Dunn RL, et al
    Reply to K.P. Weinfurt et al.
    J Clin Oncol. 2020;38:654-655.
    PubMed    
    
    
    
58. VICKERS AJ
    Reply to K.P. Weinfurt et al.
    J Clin Oncol. 2020;38:653-654.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: